Claudine Janet Diana Isaacs, MD| Cancer Genetics, Medical Oncology | MedStar Health
About me
Dr. Claudine Isaacs is a medical oncologist who specializes in the care of women with all stages of breast cancer. She is Professor of Medicine and Oncology, Associate Director of Clinical Research and Leader of the Clinical Breast Cancer Program at the Georgetown Lombardi Comprehensive Cancer Center. She is also the Medical Director of the Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research. She has been practicing for over 20 years.
Dr. Isaacs received her medical degree and internal medicine residency training at McGill University, Canada. She completed fellowship training in the Division of Hematology and Oncology at McGill University and a Fellowship in Breast Medical Oncology in the Division of Medical Oncology at Georgetown University. She then joined the faculty in the Department of Medicine and Oncology at Georgetown University.
Dr. Isaacs has extensive experience in the conduct of clinical trials focusing on all aspects of breast cancer. Additional research interests include cancer risk assessment and medical management and prevention strategies for women at high risk for breast cancer. She has served as the principal investigator of a variety of clinical trials in the treatment of early-stage and metastatic breast cancer, and currently serves as the principal investigator of the Translational Breast Cancer Research Consortium (TBCRC), the ISPY2 trial at Georgetown University. She has authored over 200 peer-reviewed publications. She has also served on a number of committees, including the Cancer Education Committee at the American Society of Clinical Oncology (ASCO), the ASCO Scientific Program Committee, the Breast Oncology Local Diseases Task Force of the Breast Steering Committee of the National Cancer Institute, and most recently the ASCO guidelines committee. She has been named one of America's Top Cancer Doctors by Castle Connolly/Newsweek for many years running, and has also received designations from Washingtonian Magazine and Women's Health Magazine.
Dr. Isaacs' Philosophy of Care:
I strive to personalize the care of my patients by tailoring state-of-the-art therapy to their individual situations and by providing them with access to cutting-edge clinical trials. Equally important is that the care of my patients extends well beyond focusing just on the optimal therapy of their cancer. My approach to care is to relate to each of my patients as individuals in the context of their lives, and not solely based on the characteristics of their disease. To that end, I work with a wonderful and dedicated multidisciplinary group of expert colleagues who are deeply committed to and involved with our patients' care. The whole team is focused solely on breast cancer and includes medical oncologists, surgeons, radiation oncologists, breast imagers, and pathologists who are supported by an experienced team of clinical nurse coordinators, nurse navigators, research nurses, genetic counselors and social workers, all championing a multidisciplinary approach to breast cancer diagnosis, treatment and recovery. We are not treating a disease. We are treating a person and we are here to provide state-of-the-art medical treatment and to accompany that person navigates their cancer journey.
Clinical areas of focus
- Breast Cancer
- Cancer Genetics Consultation
- Ductal Carcinoma In Situ (DCIS)
- Family History-Based Cancer Risk Assessment
- Genetic Mutation Testing
- Genetic Testing For Cancer Patients
- Genetic Testing For Hereditary Cancer
- Lobular Carcinoma In Situ (LCIS)
- Papillary Carcinoma Of Breast
- Transitional Cell Carcinoma
Conditions and procedures
Conditions I treat
- Breast Cancer
- Breast Cancer Complications
- Breast Cancer In Young Women
- Breast Sarcoma
- Ductal Carcinoma In Situ (DCIS)
- Estrogen Receptor
- Genetic Predisposition To Breast Cancer
- Hodgkin Disease
- Lobular Carcinoma In Situ (LCIS)
- Papillary Carcinoma Of Breast
- Transitional Cell Carcinoma
Procedures I perform
- A1c Testing
- Abdominal Wall Biopsy
- Adjuvant Hormone Therapy
- Adrenal Antibody Testing
- Antiangiogenic Therapy
- Bladder Tumor Prevention
- Bone Biopsy
- Brca Gene Testing
- Breast Biopsy
- Breast Cancer
- Breast Cancer And Fertility
- Breast Cancer Chemoprevention
- Breast Cancer Pain Management
- Breast Cancer Screening
- Breast Cancer Treatment
- Breast Density Evaluation
- Breast Infection Treatment
- Breast Lift Surgery
- Breast Seroma Aspiration
- Ca 19-9 Test
- Cancer Genetics Consultation
- Cancer Risk Assessment
- Cea Testing For Colorectal Cancer
- Chemotherapy Administration
- Circulating Tumor Cell Monitoring
- Diagnostic Breast Imaging
- Diagnostic Mammography
- Digital Breast Tomosynthesis
- Ductal Carcinoma In Situ (DCIS) Surgery
- Family History-Based Cancer Risk Assessment
- Fine Needle Aspiration Biopsy
- Fish Testing For Breast Cancer
- Genetic Counseling
- Genetic Mutation Testing
- Genomic Testing For Cancer
- High-Risk Breast Lesion Management
- Hormone Replacement Therapy
- Immunotherapy
- Intra-Arterial Infusion Of Chemotherapy
- Introduction Of Antineoplastic
- Liquid Biopsy
- Liver Biopsy
- Lumpectomy
- Lymph Node Biopsy
- Lynch Syndrome Testing
- Mammaprint Testing
- Mammography
- Mastectomy
- Methylation Profiling
- Modified Radical Mastectomy
- Pathology Consultation
- Preventive Medicine Counseling
- Prophylactic Oophorectomy
- Psa Testing
- Radiation Therapy
- Risk-Reducing Mastectomy
- Risk-Reducing Salpingo-Oophorectomy
- Selective Estrogen Receptor Modulator (SERM) Therapy
- Sentinel Lymph Node Mapping
- Targeted Genome Sequencing
- Tumor Immunohistochemistry
- Tumor Marker Testing
- Ultrasound
Insurance
MedStar Health accepts most major health insurance plans. If you are uncertain as to whether your individual health insurance plan is accepted at MedStar Health, please call your insurance company.
-
List of insurance plans we accept
- IH-Open EPO Plus
- Kaiser Permanente Signature
- CareFirst Blue Preferred PPO
- CIGNA PPO
- Choice POS II
- Anthem BCBS of VA Key Care POS/PPO/Indemnity
- MedStar Family Choice - Maryland Health Choice
- United Medicare Private Fee-for-Service (PFFS) plans
- CareFirst NASCO
- Coventry Health Care National Network PPO
- CareFirst Blue Choice Opt Out Open Access
- CIGNA EPO
- Anthem Federal Employee Program Standard
- Aetna Advantage 5750
- Aetna Medicare Advantage HMO & PPO Plans
- Aetna VA Exchange
- Medicare Advantage - Advantra Value (PPO)
- M.D. IPA Preferred (POS)
- United Healthcare Options (PPO)
- Anthem BCBS Medi Blue SNP
- Choice Fund PPO
- Cigna True Choice Medicare (PPO)
- Sentara Health
- OCI Direct (HMO)
- CIGNA SureFit (HMO)
- Anthem BCBS Medi Blue Dual Adv
- CIGNA POS/Network POS
- First Health PPO
- Healthy Blue (HMO, POS)
- BCBS Out-of-State Medicare Plans (Blue Advantage)
- First Health PPO
- United Healthcare Select Plus (POS)
- CIGNA HMO Open Access
- HUMANA/Choice Care Medicare Plans (Choice, Gold Choice)
- Kaiser Permanente Select
- United Healthcare Choice Plus Cardiac Global
- Coventry Health Care of Virginia
- Aetna Classic 5000PD
- Aetna Open Choice (PPO)
- Aetna Worker's Compensation Network
- Aetna Medicare Advantage PFFS Plan
- IH-POS Plus
- Aetna Student Health Insurance
- CareFirst (NCA) Indemnity
- CIGNA Indemnity
- CareFirst MedStar Select PPO
- Cigna Achieve Medicare (HMO C-SNP)
- HealthyBlue PPO
- Alterwood Advanatge HMO & DSNP Plans
- Coventry of Delaware HMO/PPO
- United Healthcare Select HMO - EPO/NPP
- Humana Gold Plus HMO
- IH-Open HMO Option
- IH-Open HMO
- Amerigroup DC Alliance
- United HealthCare Community Plan - Maryland Health Choice Program
- Optimum Choice & Optimum Choice Preferred (POS) Cardiac Global
- IH-EPO Plus
- Kaiser Permanente Medicare Plus
- Optima Family Care MCO - VA Medicaid MCO
- CareFirst Blue Choice Opt Out Plus Open Access (POS)
- Kaiser Permanente HMO Plus and DHMO Plus Member
- MedStar Family Choice DC Healthy Families
- Aetna Traditional Choice (PPO)
- IH-Open POS Plus
- Anthem Federal Employee Program Basic
- United Healthcare Community Plan - VA Medicaid MCO
- Great-West Healthcare POS/CIGNA
- HighMark
- Medicare FFS
- TRICARE for Life East
- Aetna Advantage 6350
- MultiPlan, Inc
- IH-POS
- OA Plus
- POS OA
- Kaiser Maryland Medicaid MCO
- Kaiser Permanente Signature - Added Choice
- Anthem BCBS of VA HealthKeepers (HMO)
- Mamsi Life & Health (Indem./PPO) Cardiac Global
- Choice Care Network/HUMANA (PPO)
- Aetna Better Health of VA
- MD IPA (HMO) & MD IPA Preferred Cardiac Global
- HumanaChoice Honor's plan PPO
- CareFirst Group Medicare Advantage
- Johns Hopkins Advantage MD HMO
- Cigna Preferred Medicare (HMO)
- Aetna Basic
- Geisinger Medicare Advantage
- CareFirst Group Medicare Advantage prescription drug benefit (PPO)
- Blue Choice Advantage
- Optimum Choice Preferred (POS)
- CareFirst Community Health Plan of MD
- AmeriHealth Caritas DC Healthy Families
- Magellan Complete Care of VA - VA Medicaid MCO
- Police and Fire Clinic
- AMERIVANTAGE/Amerigroup Community Care
- CIGNA Connect EPO
- Jai Medical Systems - Maryland Health Choice
- Mamsi Life & Health (Indem./PPO)
- IH-Open POS II
- IH-PPO
- IH-Network Only Plus
- Lasso Healthcare - Medicare Medical Savings Account
- Aetna Managed Choice (POS)
- Anthem BCBS of VA HealthKeepers Plus
- Kaiser Permanente Medicare Advantage Signature and Select
- Navigate
- CareFirst Maryland Point of Service Plan
- WellPoint Maryland - Maryland Health Choice
- MedStar Family Choice DC Healthcare Alliance
- United Healthcare Choice Plus
- Cigna TotalCare (HMO D-SNP)
- Aetna Elect Choice/ EPO (Aetna Health Fund)
- Health Services for Children with Special Needs
- M.D. IPA (HMO)
- Cigna True Choice Plus Medicare (PPO)
- CareFirst Blue Card Program
- CareFirst Administrators
- UnitedHealthcare Individual Exchange Plans
- HumanaChoice PPO
- Cigna Alliance Medicare (HMO)
- Johns Hopkins Advantage MD PLUS PPO
- Advantra Platinum (PPO)
- Aetna HMO-Open Access/Select OA/HealthFund/Health Network Option OA
- Aetna Premier 200PD
- DC/MD SHOP QHP Small Business Plans
- CareFirst Dual Prime HMO-SNP
- Private Health Care Systems (PPO)
- United Student Resources
- UnitedHealthcare Medicare Advantage DSNP District of Columbia
- CareFirst MedStar PPO
- CareFirst Maryland Indemnity or PPO
- Aetna Classic 3500
- Employee Health Plan
- BlueChoice Open Access
- Kaiser Permanente Flexible Choice 3-tier POS
- Humana Medicare Advantage - HMO Open Access
- Choice POS II Open Access
- Choice POS
- Kaiser Permanente Select Cardiac Global
- IH-Indemnity
- UHC Group Medicare Advantage Plans (HMO, POS, PPO)
- Aetna Advantage 6350PD
- Optimum Choice
- Maryland Physicians Care MCO
- Fee-for-Service (FFS) District of Columbia, Maryland and Virginia Medicaid
- UnitedHealthcare and AARP Medicare Complete Plans
- Options PPO Cardiac Global
- Beech Street PPO
- NYC Medicare Advantage Plus
- Core Essential (HMO)
- IH-HMO
- Priority Partners - Maryland Health Choice
- Kaiser Permanente Select - Added Choice
- IH-Open Network Only Plus
- CareFirst EPO
- Erickson Advantage Plans
- Aetna Elect Choice/ Open Access (POS)
- Private Fee-for-Service Plans (PFFS)
- CareFirst BlueCross BlueShield Advantage Core/Enhanced
- United Healthcare Choice Cardiac Global
- Aetna HMO
- United Healthcare Choice
- Kaiser Permanente Flexible Choice POS Cardiac Global
- TRICARE East Prime
- CareFirst Federal Employee Program (Std. & Basic PPO)
- Aetna Signature Administrator PPO/TPA
- Select HMO/HealthFund/Health Network
- Medicare Direct
- Veterans Affairs Community Care Network
- United Healthcare Select HMO-EPO/NPP Cardiac Global
- TriWest Healthcare Alliance
- Anthem BCBS Medi Blue Plus
- TRICARE East Select
- Anthem BCBS of VA HealthKeepers (POS & POS OA)
- Uniformed Services Family Health Plan
- Aetna Managed Choice Open Access (POS)
- United Healthcare Navigate Cardiac Global
- Kaiser Permaenete Signature - Added Choice Cardiac Global
- AmeriHealth Caritas DC Healthcare Alliance
- CIGNA HMO & Network (HMO)
- UnitedHealthcare Medicare Adv. Special Needs Plans
- CareFirst FEP Blue Focus
- CIGNA PPO Plus
- Johns Hopkins Advantage MD PPO
- Aetna Quality Point of Service (POS)
- Humana Medicare Advantage - PPO
- Aetna Better Health of MD
- Aetna Classic 5000
- Network OA
- Tricare Reserve Select
- Amerigroup DC Healthy Families
- BCBS of Michigan (BCN Advantage,Security Blue, Freedom, Medicare PLUS Blue Group PPO)
- UHC Passport
- CareFirst BlueChoice HMO
Videos
Education
Board Certification: American Board of Internal Medicine, Medical Oncology
Fellowship: Georgetown University School of Medicine GME (1993)
Fellowship: McGill University (1992)
Residency: McGill University Faculty of Medicine (1990)
Internship: Montreal General Hospital (1988)
Medical School: McGill University (1987)
Awards
- America’s Top Doctors for Women, Women’s Health Magazine
- Marquis Who’s Who in America
- America’s Top Doctors, Castle Connolly
- Newsweek’s Top Cancer Doctors
- Top Doctors Washington DC, Washingtonian Magazine
- Global Directory Top Doctors
- Global Directory of Who’s Who
- Top Doctors Washington DC Area, Northern Virginia Magazine
- Estelle Ramey Mentorship Award, Georgetown University School of Medicine
Hospital affiliations
News and publications
- Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, Rao SB, Eng-Wong J, Seillier-Moiseiwitsch F, Noone AM, Isaacs C. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009;27(31):5153-9. PMID 19752342
- Schwartz M, Peshkin B, Hughes C, Main D, Isaacs C, Lerman C. Impact of BRCA1/BRCA2 mutation testing on psychological distress in a clinic-based sample. J Clin Oncol 2002;20:514-520.
- Isaacs C, Peshkin BN, Schwartz M, DeMarco TA, Main D, Lerman C. Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer. Breast Cancer Res and Treat 2002;71:103-112.
- Lehman CD, Isaacs C, Schnall MD, Pisano ED, Ascher SM, Weatherall PT, Bluemke DA, Bowen DJ, Marcom PK, Armstrong DK, et al. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology 2007;244(2):381-8.
- Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer. 2011;118:510-517
- Mandelblatt JS, Faul LA, Luta G, Makgoeng SB, Isaacs C, Taylor K, Sheppard VB, Tallarico M, Barry WT, Cohen HJ. Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901. J Clin Oncol 2012;(21):2609-14.
- Sheppard VB, Isaacs C, Luta G. Narrowing the racial gaps in breast cancer chemotherapy initiation: the role of the patient-provider relationship. Breast Cancer Res Treat. 2013 May;139(1):207-16.
- Potosky, A. L., O'Neill, S. C., Isaacs, C., Tsai, H.-T., Chao, C., Liu, C., Ekezue, B. F., Selvam, N., Kessler, L. G., Zhou, Y. and Schwartz, M. D. Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years. Cancer. 2015;121(22):4062-70.
- Budd, G. T., Barlow, W. E., Moore, H. C., Hobday, T. J., Stewart, J. A., Isaacs, C., Salim M, Cho J, Rinn K, Albain K, Chew H, Burton G, Moore TD, Srkalovic G, McGregor B, Flaherty L, Livingston R, Lew D, Gralow J, Hortobagyi, G. N. SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. J Clin Oncol, 2015;33(1), 58-64. PMID 25422488
- Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 7;375(1):11-22. PMID: 27406346
- Zhang X, Chiang HC, Wang Y, Zhang C, Smith S, Zhao X, Nair SJ, Michalek J, Jatoi I, Lautner M, Oliver B, Wang H, Petit A, Soler T, Brunet J, Mateo F, Angel Pujana M, Poggi E, Chaldekas K, Isaacs C, Peshkin BN, Ochoa O, Chedin F, Theoharis C, Sun LZ, Curiel TJ, Elledge R, Jin VX, Hu Y, Li R. Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis. Nat Commun. 2017 Jun 26;8:15908. PMID: 28649985; PMCID: PMC5490191.
- Mandelblatt JS, Small BJ, Luta G, Hurria A, Jim H, McDonald BC, Graham D, Zhou X, Clapp J, Zhai W, Breen E, Carroll JE, Denduluri N, Dilawari A, Extermann M, Isaacs C, Jacobsen PB, Kobayashi LC, Nudelman KH, Root J, Stern RA, Tometich D, Turner R, VanMeter JW, Saykin AJ, and Ahles T. Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study. J Clin Oncol 2018. DOI: 10.1200/JCO.18.00140. PMID 30281396
- Pohlmann PR, Isaacs C. Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few. J Natl Cancer Inst. 2018 Jan 1;110(1). PMID: 28922782
- Qian F, Wang S, Mitchell J, McGuffog L, Barrowdale D, Leslie G, for CIMBA. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. 2018 Oct 12. doi: 10.1093/jnci/djy132. PMID: 30312457
- Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, Baker TM, Marshall JL, Isaacs C. Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00286. Epub 2018 Jul 23. PMID:30234181
- Wood ME, Garber JE, Isaacs C, Masood S, Bedrosian I, Tung N, Chun J, Schnabel FR, Arun BK; International Society of Cancer Risk Assessment and Management. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. Breast J. 2019 Jul;25(4):575-577. PMID: 31280501
- Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien J, Forero-Tores A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, et al, for the I-SPY 2 Investigators. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020;6(5):676-684
- Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, et al for ISPY2. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1355-1362. PMID: 32701140; PMCID: PMC7378873.
- Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, Dragun A, Gelpi JB, Hofstatter EW, Isaacs CJ, Jatoi I, Kennedy E, Litton JK, Mayr NA, Qamar RD, Trombetta MG, Harvey BE, Somerfield MR, Zakalik D. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol. 2020 Jun 20;38(18):2080-2106. PubMed PMID: 32243226.
- Chandler Y, Jayasekera J, Schechter C, Isaacs C, Cadham C, Mandelblatt J. Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores. J Natl Cancer Inst. 2020 Jun 1;112(6):574-581. PMID: 31612208
- Ambrosone CB, Zirpoli GR, Hutson AD, McCann WE, McCann SE, Barlow WE, Kelly KM, Cannioto R, Sucheston-Campbell LE, Hershman DL, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Budd GT, Albain KS. Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol. 2020 Mar 10;38(8):804-814. PMID: 31855498; PMCID: PMC7062457.
- O'Neill SC, Taylor KL, Clapp J, Jayasekera J, Isaacs C, Mary Atieh Graham D, Goldberg SL, Mandelblatt J. Multilevel Influences on Patient-Oncologist Communication about Genomic Test Results: Oncologist Perspectives.J Health Commun. 2018;23(7):679-686. PMID:30130477
- Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 Apr 1;38(10):1059-1069. PMID: 32031889; PMCID: PMC7106976.
- Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 May 1;6(5):676-684. PMID: 32053137; PMCID: PMC7058271.
- Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Shen F, Storniolo AMV, Badve S, Ballinger TJ, Chang CL, Zhong Y, Savran C, Miller KD, Schneider BP. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1410-1415. PMID: 32644110; PMCID: PMC7349081.